Alternatives to Rehydra+ Wellness

$99/mo semaglutide, $183/mo tirzepatide, all 50 states, a named physician personally reviewing every intake, and a real 5-7 day timeline — on a broader peptide platform where GLP-1 pricing is genuinely invisible unless you know to pull the page's own data bundle.

This record changed completely between checks, and mostly for the better. The founding-member framing that dominated it a week ago is gone: read live on 2026-08-26 KERNX simply says "Semaglutide starts at $129/month and Tirzepatide starts at $229/month. Pricing varies by prescribed dose. No membership fee. No required 3 month plan." What has not gone is the cost outside those figures, and KERNX is unusually straight about it — a provider consultation fee applies when treatment is approved, at $25 for a message-based review, $35 for a standard live visit or $60 for a complex live visit. Two more things this record previously had wrong. It does say where it operates: licensed providers in all 50 states, repeated in its banner and its FAQ. And it publishes a real timeline: a free five-minute assessment, provider review typically within 24 hours, pharmacy processing 1–2 business days and transit 2–3, so most first orders arrive within three to five business days of approval. It also says nothing is charged until a provider approves you.

No video visit and no membership fee — semaglutide from $117.96/mo, tirzepatide from $178.98/mo — but Trava's own pages currently disagree with each other on its clinical-partner name and its cheapest semaglutide price.

Trellis Vitality is the cheapest genuinely-disclosed option on this page: $150 a month for compounded semaglutide and $199 for tirzepatide, month to month, with every dosage available at the same price and no membership fee, no consult fee and a $0 assessment. Commit for three or six months and those fall to $140/$133 and $189/$179. It names the pharmacy that compounds the medication — Vials Rx, described as a US state-licensed, cGMP-compliant facility — which is the disclosure most of its cheaper competitors skip, and it covers all 50 states with board-certified clinicians reviewing intake. The caveats are about what it doesn't sell and doesn't say. There is no FDA-approved brand option, no oral formulation, and none of its pricing appears on the homepage at all — you have to reach the GLP-1 product page to find a single number, which makes it look more opaque than it actually is. There is also no postpartum, breastfeeding or PCOS content anywhere.

A named-Medical-Director program licensed in all 50 states, from $99/mo semaglutide and $183/mo tirzepatide, with no membership required — but it carries a 2025 FDA warning letter over how it described its compounded medication, and both prices are 'From' starting prices rather than a guaranteed working-dose rate.

Flat at every dose - $99 semaglutide, $134 tirzepatide, all fifty states - which makes the annual math trivial. The site never names its operating company.

One of the lowest disclosed GLP-1 starting prices in this round — from $99/mo semaglutide, $133/mo tirzepatide — with an explicit no-membership, no-hidden-fee claim, though the real ongoing rate at a working dose isn't confirmed.

A twenty-year weight-loss operator rather than a telehealth startup, selling compounded semaglutide at $149 a month to month and tirzepatide at $239, medication and clinical care in one price with no separate membership fee. The cheaper $116 and $159 figures it leads with are three-month plans, and there is a catch its own FAQ spells out: those plans bill every ten weeks, not every twelve. That is 5.2 charges a year instead of 4, which turns an advertised $116 a month into roughly $151 a calendar month. Read it as a real discount, just a smaller one than the number suggests. It ships to all 50 states, holds a BMI floor of 26, and excludes anyone pregnant or breastfeeding.

A multi-category telehealth shop with some of the lowest disclosed GLP-1 starting prices in this batch — from $99/mo semaglutide, $140/mo tirzepatide — though the site's own disclosure that pricing 'may vary' means the real ongoing cost isn't fully locked in.